| Net profit of Bafna Pharmaceuticals rose 109.92% to Rs 2.75 crore in the quarter ended March 2026 as against Rs 1.31 crore during the previous quarter ended March 2025. Sales rose 8.14% to Rs 42.24 crore in the quarter ended March 2026 as against Rs 39.06 crore during the previous quarter ended March 2025.
For the full year,net profit rose 167.47% to Rs 11.10 crore in the year ended March 2026 as against Rs 4.15 crore during the previous year ended March 2025. Sales rose 3.26% to Rs 150.62 crore in the year ended March 2026 as against Rs 145.86 crore during the previous year ended March 2025.
| Particulars | Quarter Ended | Year Ended | | Mar. 2026 | Mar. 2025 | % Var. | Mar. 2026 | Mar. 2025 | % Var. |
| Sales | 42.24 | 39.06 | 8 | 150.62 | 145.86 | 3 |
| OPM % | 8.40 | 7.96 | - | 10.58 | 7.66 | - |
| PBDT | 4.28 | 3.32 | 29 | 17.04 | 11.19 | 52 |
| PBT | 2.62 | 3.10 | -15 | 10.97 | 6.30 | 74 |
| NP | 2.75 | 1.31 | 110 | 11.10 | 4.15 | 167 |
|